High prevalence of genital HPV infection among long-term monogamous partners of women with cervical dysplasia or genital warts-Another reason for HPV vaccination of boys

Human papillomavirus, or HPV, is a common sexually transmitted disease, most often acquired during the adolescence or the early 20s. It can be divided into oncogenic and nononcogenic serotypes. It is responsible for genital warts as well as pathologic diseases that can lead to genital cancers and cancers of the oropharyngeal tract in both males and females. The majority of adolescents who acquire HPV infections do not go on to develop cancer. New discoveries about the virus’ persistence and latency direct how we treat adolescents with HPV infections. Recommendations for prevention of HPV include use of the 9-valent vaccine against the most common oncogenic HPV serotypes. Screening should be delayed until the age of 21, with the exception of immunocompromised women. The HPV vaccination is safe and effective, and does not encourage sexual activity among adolescents. Both boys and girls should be vaccinated against HPV at 11 to 12 years of age but may receive the vaccination as early as 9 or as late as 21 (males) or 26 (females) years of age. The vaccine may now also be given in only two doses if the series was started before the age of 15. Follow-up studies in the years after the vaccine’s introduction have shown large decreases in HPV infection rates. This review contains 7 figures, 7 tables and 63 references Key Words: Oncogenic subtype, Oropharyngeal cancer, Infection persistence, Immune tolerance, Cervical dysplasia, Genital warts, 9-valent vaccine, Vaccine safety

Download Full-text

Random Network Models to Predict the Long-Term Impact of HPV Vaccination on Genital Warts

Viruses ◽

10.3390/v9100300 ◽

2017 ◽

Vol 9 (10) ◽

pp. 300 ◽

Cited By ~ 4

Author(s):

Javier Díez-Domingo ◽

Víctor Sánchez-Alonso ◽

Rafael-J. Villanueva ◽

Luis Acedo ◽

José-Antonio Moraño ◽

...

Keyword(s):

Random Network ◽

Hpv Vaccination ◽

Network Models ◽

Genital Warts ◽

Long Term Impact

Download Full-text

HIV-positive MSM’s knowledge of HPV and anal cancer self-sampling: A scoping review

Current Oncology ◽

10.3747/co.25.3856 ◽

2018 ◽

Vol 25 (1) ◽

pp. 83 ◽

Cited By ~ 7

Author(s):

M.K.L. Poon ◽

J.P.H. Wong ◽

A.T.W. Li ◽

M. Manuba ◽

A. Bisignano ◽

...

Keyword(s):

Anal Cancer ◽

Scoping Review ◽

Cancer Education ◽

Hpv Vaccination ◽

Cell Cancer ◽

Hpv Infection ◽

Hiv Positive ◽

Policy Makers ◽

High Prevalence ◽

Sex With Men

Human papillomavirus (hpv) infection is the cause of anal squamous cell cancer (ascc) in 80% of cases. Available research has also shown high prevalence of anal hpv infection among men who have sex with men (msm). However, hpv vaccination is low among msm in Canada. In light of this information, we conducted a scoping review with the aim of exploring (1) the knowledge of hpv and anal cancer among hiv-positive msm and (2) the acceptability of hpv and anal cancer self-sampling in this population. In conducting the review, we searched five electronic databases for peer-reviewed articles and abstracts published in English, between 2007 and 2017. A total of 803 articles were retrieved; after accounting for duplicates (n=40) and unmet criteria (n=754), a total of 794 articles were excluded. A final total of nine articles were used in this review. Results of this review show that hiv-positive msm have limited knowledge regarding the risks of anal cancer associated with hiv and hpv coinfection. Furthermore, there is limited research on hpv and anal cancer self-sampling in this population. However, the review of available studies suggested that hiv-positive msm were open to anal cancer self-sampling. It also identified potential barriers to self-sampling. In conclusion, we provide suggestions and future directions for policy-makers and educators to develop inclusive and accessible strategies to reach hiv-positive msm regarding anal cancer education and self-screening.

Download Full-text

High prevalence of Papillomavirus (HPV) infection in asymptomatic male partners of females with genital warts: An underestimated condition

The Gazette of Medical Sciences ◽

10.46766/thegms.virology.21053106 ◽

2021 ◽

Vol 2 (3) ◽

pp. 42-45

Author(s):

Marco Ghezzi ◽

◽

Alberto Cescato ◽

Giovanni Bisonni ◽

Edoardo Albertin ◽

...

Keyword(s):

Human Papillomavirus ◽

Male Infertility ◽

Genital Warts ◽

Hpv Infection ◽

Male Partners ◽

Sexually Transmitted ◽

High Prevalence

Human Papillomavirus (HPV) infection is one of the most common sexually transmitted condition in both genders and is responsible for penile, oral, neck and anal cancers in men. However, seminal HPV infection may contribute to the risk of male infertility.

Download Full-text

Concordance of HPV-DNA in cervical dysplasia or genital warts in women and their monogamous long-term male partners

Journal of Medical Virology ◽

10.1002/jmv.24824 ◽

2017 ◽

Vol 89 (9) ◽

pp. 1662-1670 ◽

Cited By ~ 2

Author(s):

Filip Rob ◽

Ruth Tachezy ◽

Tomáš Pichlík ◽

Petr Škapa ◽

Lukáš Rob ◽

...

Keyword(s):

Cervical Dysplasia ◽

Genital Warts ◽

Male Partners ◽

Hpv Dna

Download Full-text

Warts and all: Fingolimod and unusual HPV-associated lesions

Multiple Sclerosis Journal ◽

10.1177/1352458518807088 ◽

2018 ◽

Vol 25 (11) ◽

pp. 1547-1550 ◽

Cited By ~ 9

Author(s):

James Triplett ◽

Allan G Kermode ◽

Alastair Corbett ◽

Stephen W Reddel

Keyword(s):

Viral Infections ◽

Hpv Vaccination ◽

Hpv Infection ◽

Cancer Surveillance ◽

Varicella Zoster ◽

Associated Lesions ◽

Increased Risk ◽

High Prevalence ◽

Sphingosine 1 Phosphate ◽

Relapsing Remitting Multiple Sclerosis

Background: Fingolimod is used to reduce relapse rates in relapsing-remitting multiple sclerosis (MS). It is a sphingosine 1-phosphate (S1P) analogue having antagonistic effects on S1P receptors. Its immunosuppressive effect is due to reduced circulating lymphocyte numbers, and it may also be associated with impaired intrinsic cancer surveillance. Fingolimod side effects include increased rates and severity of viral infections particularly varicella zoster. Methods: We present five cases of chronic and treatment refractory warts associated with fingolimod therapy. Results: Each of the five cases presenting with chronic warts while receiving fingolimod therapy had prolonged periods of lymphopenia and improvements were seen following dose reduction or cessation of fingolimod. Conclusion: Cutaneous warts are associated with human papilloma virus (HPV) infection, suggesting an increased risk of other HPV-driven conditions such as cervical cancer following fingolimod administration. HPV viruses are responsible for approximately 90% of cervical cancers as well as a significant portion of anogenital cancers and have a high prevalence in sexually active adults. Given the reduced immune response to viral infections and potential impaired cancer surveillance in those receiving fingolimod, HPV vaccination and frequent assessment for the development of HPV-associated malignancies are recommended.

Download Full-text

020 Increased risk of an abnormal cervical screening test in women with MS exposed to high-efficacy disease-modifying treatments

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp-2019-anzan.19 ◽

2019 ◽

Vol 90 (e7) ◽

pp. A7.3-A7

Author(s):

Anneke Van der Walt ◽

Jeremy Yuvaraj ◽

Jim Stankovich ◽

Nicola McGuinn ◽

Louise Rath ◽

...

Keyword(s):

Vaccine Coverage ◽

Cervical Screening ◽

Hpv Vaccination ◽

Cervical Dysplasia ◽

Previous History ◽

Screening Tests ◽

High Efficacy ◽

Increased Risk ◽

History Of

IntroductionLong-term exposure of women with Multiple sclerosis (MS, wwMS) to immunomodulatory or immunosuppressive treatments may increase the risk of cervical dysplasia. However, little is known about cervical dysplasia risk and Human Papillomavirus (HPV)-vaccine coverage in wwMS.MethodsAdult wwMS were recruited from two tertiary MS clinics. To explore the association between MS treatments (DMTs) and abnormal cervical screening tests (CSTs), we linked individual data from MSBase, the Victorian Cervical Screening Registry, and National HPV vaccination program registry (NHPVPR).ResultsTo date, we have recruited 208 wwMS of whom 102 had complete data (vaccination status, cervical screening tests, MSBase data) and no previous history of abnormal CST at MS onset for this interim analysis. The average age was 33.8 (18 to 59 yrs) and most (n=58, 88%) were unvaccinated. 19 wwMS (19%) had an abnormal CST after MS onset (incidence rate 20.6 cases/1000 person-years, 95% confidence interval 12.4–32.1) over average 9.0 years of follow-up. 57 wwMS were treated with lower-efficacy therapies (56%), 73 with a high-efficacy therapy (72%), and 44 were exposed to both. Eight abnormal CSTs were detected before starting high-efficacy therapy (rate 12.6, 95% CI (5.4–24.8)) and 11 were detected after starting high-efficacy therapy (rate 38.6, 95% CI (19.3–69.0), p=0.022.ConclusionWe provide preliminary data that high efficacy DMTs may increase the risk of abnormal CSTs over time. A larger cohort and inclusion of additional cervical dysplasia risk factors are required to fully elucidate risk in wwMS.

Download Full-text

50: Increased Risk of Cervical Dysplasia in Long Term Survivors of Allogeneic Stem Cell Transplantation – Implications for Screening and HPV Vaccination

Biology of Blood and Marrow Transplantation ◽

10.1016/j.bbmt.2007.12.058 ◽

2008 ◽

Vol 14 (2) ◽

pp. 20-21 ◽

Cited By ~ 2

Author(s):

B.N. Savani ◽

A. Shenoy ◽

P. Stratton ◽

A. Filie ◽

E. Kozanas ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Allogeneic Stem Cell Transplantation ◽

Hpv Vaccination ◽

Cervical Dysplasia ◽

Increased Risk ◽

Long Term Survivors

Download Full-text

Geographic distribution of cervical cancer-associated human leucocyte antigens and cervical cancer incidence in Finland

International Journal of STD & AIDS ◽

10.1258/095646207782193803 ◽

2007 ◽

Vol 18 (10) ◽

pp. 672-679 ◽

Cited By ~ 7

Author(s):

Felipe A Castro ◽

Katri Haimila ◽

Kari Pasanen ◽

Marjo Kaasila ◽

Toni Patama ◽

...

Keyword(s):

Cervical Cancer ◽

Geographic Distribution ◽

Persistent Infection ◽

Hpv Vaccination ◽

Hpv Infection ◽

Susceptibility Genes ◽

Red Cross ◽

Distribution Maps ◽

Human Leucocyte Antigens

Cervical cancer (CxCa) is a long-term sequelae caused by persistent human papillomavirus (HPV) infection. Genetic susceptibility to the persistent infection and CxCa is associated with certain human leucocyte antigen (HLA) types. The same susceptibility genes may also determine whether a woman will be protected against the persistent infection and against CxCa by HPV vaccination or not. A systematic review of literature identified following HLAs to be associated with CxCa: A11 (odds ratio [OR] = 1.4, 95% confidence interval [CI] 1.1–2.0); B7 (1.5, 1.1–2.0); B15 (0.6, 0.4–0.8); DR2 (1.2, 1.1–1.4) and DR6 (0.6, 0.5–0.8). In the Caucasian population, HLA-B7 and DR6, and DR2 and B15 antigens showed at least borderline associations. In view of a bone marrow donor registry at the Finnish Red Cross and the Finnish Cancer Registry, we created geographic distribution maps of index HLA frequencies and CxCa incidence in the fertile-aged Finnish population. Increased incidence of CxCa was found in a region of western coastal Finland, where frequency of two CxCa susceptibility genes (HLA-DR2 and B7) was increased, and frequency of one CxCa resistance gene (HLA-B15) was decreased. Whether or not HLA type determines also regional susceptibility to persistent HPV infection, and the success of HPV vaccination in preventing both the persistent infection and CxCa warrants further investigation.

Download Full-text